Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Carboplatin in Metastatic or Relapsed SCLC
NCT00387660Phase 2Completed
- Sponsor
- University of California, Davis
- Start
- Oct 2001
- Primary completion
- Aug 2008
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in small cell lung cancer (SCLC) (2 arms), sponsored by University of California, Davis. Primary endpoint: Overall Response Rate up to 36 months. Started Oct 2001; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00387660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387660.